A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status
To access this article, please choose from the options below
M.E.P. has nothing to disclose. M.A. has nothing to disclose. S.A. has nothing to disclose. A.R. has nothing to disclose. A.Z. has nothing to disclose. T.K. has nothing to disclose. V.F. has nothing to disclose. E.H.S. has nothing to disclose.
PII: S0015-0282(08)04057-0
doi:10.1016/j.fertnstert.2008.09.064
© 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

